EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients



Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients



European Journal of Cancer 32A(10): 1809-1811



The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m-3, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged gtoreq 70 years = 23, median performance status = 80, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were evaluable. One complete remission and 22 partial remissions were noted (30.2% response rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNB is a reasonable option for advanced NSCLC, particularly in elderly patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 009724607

Download citation: RISBibTeXText

PMID: 8983294

DOI: 10.1016/0959-8049(96)00190-6



Related references

The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6 Suppl 1: 4-7, 2001

Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. Journal of the National Cancer Institute 91(1): 66-72, 1999

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 18(13): 2529-2536, 2000

Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients. Journal of the Medical Association of Thailand 87(4): 367-371, 2004

Planned sequence of gemcitabine followed by vinorelbine in the treatment of elderly patients with advanced non-small cell lung cancer. Anticancer Research 26(2b): 1501-1505, 2006

Pemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patients. Molecular and Clinical Oncology 1(3): 553-557, 2014

Gemcitabine plus vinorelbine as the second-line treatment and beyond in elderly patients with platinum-pretreated advanced non-small cell lung cancer. ChemoTherapy 60(4): 267-273, 2015

Oral vinorelbine as single-agent first-line treatment in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC). 2007

Vinorelbine (VRL) plus gemcitabine (GEM) as first-line treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC): molecular correlates. 2007

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. European Journal of Cancer 33(3): 392-397, 1997

Vinorelbine plus best supportive care vs BSC in the treatment of advanced non-small cell lung cancer elderly patients Results of a phase III randomized trial. British Journal of Cancer 78(SUPPL 2): 3, 1998

Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34 Suppl 4(): S65-S69, 2001

Docetaxel vs. vinorelbine in elderly patients with advanced non-small-cell lung cancer. Clinical Lung Cancer 13(5): 396; Author Reply 397-396; Author Reply 397, 2013

Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs & Aging 19(9): 695-721, 2002